ANDA 86187, held by NexGen Pharma. Brompheniramine Maleate.
As of Nov 21, 2026, ANDA 86187 (Brompheniramine Maleate), held by NexGen Pharma, was first approved by FDA on Aug 24, 1978, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 24, 1978 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Brompheniramine Maleate4MG · tablet;oral | Brompheniramine Maleate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters